- Clinical Trials
Expansion enables full commercial scale plasmid DNA manufacturing capabilities
Newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies
AUSTIN, Texas & CAMBRIDGE, Mass.— (August 6, 2019) — Genprex, Inc.
Thermo Fisher recently announced it is buying Brammer Bio, which provides viral vector manufacturing services for gene and cell therapy companies. This acquisition is one of the many we have seen recently, as several other large pharmaceutical companies have been acquiring emerging gene and cell therapy companies with promising drug pipelines or drug approvals, including Roche’s acquisition of Spark Therapeutics, Biogen’s buying of Nightstar Therapeutics and Pfizer’s purchase of Vivet Therapeutics….